AI-Powered Platform for Allosteric Drug Discovery

Repair Biotech is a pioneering AI-driven biopharmaceutical venture spun off from the Centre for Regenerative Medicine and Health (CRMH), Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences. The company overcomes the intrinsic limitations of conventional active-site drug targeting by pioneering allosteric modulation, which avoids active-site competitive binding to achieve superior drug safety, potency, and selectivity. At the core of Repair Biotech is its proprietary **Allo Agent** AI platform, integrating deep learning algorithms for allosteric site identification, virtual screening, binding affinity prediction, and _de novo_ molecular generation. This platform accelerates lead discovery by 60% and optimizes precision across complex biological targets. Repair Biotech has established a robust pipeline focused on high-unmet-need musculoskeletal and degenerative disorders: * **YGSI-001 (SOST allosteric modulator)**: A first-in-class small molecule for osteoporosis ($K\_d = 0.94\\text{ nM}$) that promotes bone formation and inhibits resorption while eliminating the cardiovascular black-box risks associated with standard SOST antibodies. * **YGSI-004 (CCR2 allosteric inhibitor)**: A potent non-opioid therapeutic ($K\_d = 6.6\\text{ nM}$) providing both substantial osteoarthritis pain relief and disease-modifying cartilage protection (DMOAD). * **Broader Pipeline**: Ongoing early-stage assets addressing Alzheimer’s disease (YGSI-002) and cartilage metabolism (YGSI-003).